Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Utafiti wa Awamu ya IV unaotarajiwa× | Utafiti wa Kikundi cha Wanafunzi wanaotarajiwa× | |
|---|---|---|
| Nyanja | Epidemiolojia | Epidemiolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 1970s–1980s (formalized in post-marketing regulatory frameworks) | 1950s (systematic application); conceptual roots earlier |
| Mwanzilishi≠ | Regulatory and pharmaceutical research community (ICH E2E, EMA PASS guidelines) | Richard Doll and Austin Bradford Hill (landmark application, 1951-1954); cohort methodology formalised by modern epidemiology textbooks |
| Aina≠ | Observational / interventional post-marketing study design | Observational longitudinal study design |
| Chanzo asilia≠ | Strom, B.L. (Ed.). (2005). Pharmacoepidemiology (4th ed.). Wiley. ISBN: 978-0470863088 | Rothman, K. J., Greenland, S., & Lash, T. L. (2008). Modern Epidemiology (3rd ed.). Lippincott Williams & Wilkins. ISBN: 978-0781755641 |
| Majina mbadala | prospective post-marketing surveillance study, prospective pharmacovigilance study, prospective post-authorization safety study, PASS (prospective) | longitudinal cohort study, prospective follow-up study, incidence study, prospective observational cohort |
| Zinazohusiana≠ | 5 | 6 |
| Muhtasari≠ | A prospective Phase IV study is a post-marketing investigation conducted after a drug, device, or intervention has received regulatory approval, following participants forward in real time to collect safety, effectiveness, and utilization data under routine clinical practice conditions. Unlike retrospective designs that mine existing records, prospective enrollment allows pre-specified data collection, defined follow-up windows, and direct measurement of outcomes as they occur, making it central to post-authorization safety surveillance and long-term effectiveness research. | A prospective cohort study assembles a group of participants who are free of the outcome of interest at baseline, measures their exposures, and then follows them forward in time to record who develops the outcome. By collecting exposure data before outcomes occur, it establishes a clear temporal sequence that supports causal inference — a major advantage over retrospective designs. It is the cornerstone observational method in epidemiology and clinical research. |
| ScholarGateSeti ya data ↗ |
|
|